The Turkish Journal of Pediatrics 2006 , Vol 48 , Num 3
Use of bisphosphonates for resistant hypercalcemia in children with acute lymphoblastic leukemia: report of two cases and review of the literature
1Divisions of Endocrinology, Hacettepe University Faculty of Medicine, Ankara, Turkey
2Department of Pediatrics, Hematology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Andıran N, Alikaşifoğlu A, Küpeli S, Yetgin S. Use of bisphosphonates for resistant hypercalcemia in children with acute lymphoblastic leukemia: report of two cases and review of the literature. Turk J Pediatr 2006; 48: 248-252.

Hypercalcemia is a rare complication of malignancy in children. We present two children, one of whom is the youngest reported, with CALLA+ B-cell acute lymphoblastic leukemia (ALL) who developed hypercalcemia at the time of diagnosis and were treated with relatively low-dose (0.5 mg/kg) intravenous pamidronate successive to conventional therapy. No major side effects were encountered except transient hypocalcemia and hypophosphatemia, which were easily managed by replacement therapy.

Bisphosphonate therapy was found to be beneficial for the treatment of resistant hypercalcemia associated with ALL, even at relatively low doses. Keywords : bisphosphonate, hypercalcemia, ALL

Copyright © 2016 turkishjournalpediatrics.org